SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and modestly raised its full-year outlook, but the stock is selling off to a new 52-week low. Traders are split between short sellers focused on weak revenue trends and competitive risks, and bulls who see the cash balance and buyback authorization as support for an undervalued business.

Basic Attention Token (BAT) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Basic Attention Token has a current supply of 1,500,000,000 with 1,495,724,656.95260575 in circulation. The last known price of Basic Attention Token is 0.13064027 USD and is up 2.94 over the last 24 hours. It is currently trading on 591 active market(s) with $15,372,551.09 traded over the last 24 hours. More information can be found at https://basicattentiontoken.org/.

Basic Attention Token

BATs sharp move higher is drawing attention as traders point to technical breakout momentum and a broader pickup in altcoins; no specific token-related catalyst is clearly confirmed. The community is largely bullish on continuation, while others warn about profit-taking and a possible pullback after the rally.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of the expected Q4 Phase 3 topline readout for HLP003, its investigational adjunctive treatment for major depressive disorder. Traders are split between optimism that positive data could validate the program and concern about the binary trial risk, potential dilution, and recent weak price action.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,020,742,700.022444 with 95,020,750,177.733244 in circulation. The last known price of TRON is 0.3287714 USD and is down -6.58 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,904,975,878.16 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for a sharp decline and underperforming other altcoins that traders describe as green; bearish chart setups and talk of a corrective pullback contrast with holders viewing the weakness as a pause in its longer-term climb.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

Natural gas weakness tied to mild-weather forecasts and ample storage is the dominant topic, with traders noting the price slide and looking for lower entry points. Some are buying dips in anticipation of winter cold or a sharp weather-driven rebound, while others remain bearish on warm-winter risk and persistent supply.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A quarterly earnings beat and higher full-year sales outlook, driven by demand for Mounjaro and Zepbound, have fueled LLYs advance to record highs. Traders are largely bullish on the growth, while some question the valuation and point to lower profit guidance from acquisition charges and weaker Foundayo sales amid competition in oral obesity drugs.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu is selling off alongside Brazilian equities after Lulas reelection prompted investors to reassess the countrys political and fiscal outlook; traders note the move appears macro-driven rather than tied to new company news. The community is divided between viewing the drop as an overreaction and buying opportunity and worrying about Nus heavy exposure to Brazil and the risks of its policy environment.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.42916419 USD and is up 8.20 over the last 24 hours. It is currently trading on 2313 active market(s) with $611,471,639.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINK is drawing attention for a sharp rebound and renewed buying momentum, with traders watching whether it can clear resistance and sustain a breakout. Bulls are accumulating and pointing to Chainlinks role in institutional tokenization and interoperability, while skeptics warn that the rally could fade and question whether network adoption translates into value for the token.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

A reported major Binance security breach has fueled crypto-market concern and Bitcoin selling, weighing on Strategy as a Bitcoin proxy. Traders are split between viewing the selloff as a buying opportunity and warning of further downside; Q3 revenue concerns and the CFO transition add to the bearish debate.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is drawing attention amid a sharp selloff across data-center and AI-infrastructure stocks, as traders debate concerns about AI demand, project financing, execution risk, and higher yields. Bears see further downside and question the companys ability to turn its buildout into profits, while bulls call the decline an overreaction and point to long-term data-center demand and HUTs Bitcoin exposure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million.
bioAffinity Technologies (NASDAQ:BIAF) sharesread more...

Digestive Health Expansion Sends This Microcap Soaring

Digestive health has become a sizable consumer-health category as patients increasingly look beyond short-term symptom relief toward products designed for regular use. In the U.S. alone, the digestive and gut health supplement market is estimated at $4.16 billion by one industry estimate, creating a broad commercial opportunity for companies that can carve out focused niches within the category.Shares of Immuron Limited (NASDAQ: IMRN) are surging Friday after the Australian biopharmaceutical company announced an exclusive U.S. distribution agreement with Sweden-based Calmino group AB for ...

IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today? 

Equity

Immuron signed an agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million.
Akanda (NASDAQ:AKAN) shares increased by 27.52% to $4.68.read more...

Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up

(RTTNews) - Australian biopharmaceutical company Immuron Ltd. (IMC.AX, IMRN), announced on Friday that it has signed an exclusive distribution deal with Sweden's Calmino group AB to launch its digestive health product PROIBS in the United States, following its rollout in Australi...

Immuron Takes PROIBS to America, as New U.S. Growth Engine Could be Taking Shape

Immuron (NASDAQ:IMRN) is adding another potentially important piece to its U.S. commercial strategy, announcing an exclusive distribution agreement with Sweden’s Calmino group AB to bring PROIBS to the American market. The move expands Immuron’s digestive-health portfolio beyond Travelan and gives the company another commercial product aimed at a large and recurring consumer-health need: the symptoms associated with irritable bowel syndrome. Importantly, this is not a molecule sitting years away from commercialization. PROIBS has already been sold in Sweden for more than a decade and, according to Calmino, was the best-selling IBS product in Swedish pharmacies during 2025, based on IQVIA sales data.

Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 


Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

Immuron Limited - ADR

Neutral Sentiment

<ul class="summary-bullets"><li>Proibs is a medical device used to relieve abdominal pain, bloating, diarrhea and constipation.</li><li>The company said it is targeting a portion of the U.S. digestive and gut-health supplement market, which it estimates at $4.16 billion.</li><li>In a study involving 1,003 users, 94% said Proibs was helpful, and 91% reported an improvement in daily life.</li></ul>Shares of Immuron (IMRN) surged more than 60% on Friday after the biopharmaceutical company signed an exclusive agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S.<a href="https://stocktwits.com/symbol/IMRN">IMRN stock</a> hit its highest levels since November 2025 and is on track to clock its biggest single-day gains since March 2024.<h2 class="st-heading-2">IMRN To Tap Into $4.2B Gut Health Market</h2>Proibs is a medical device used to relieve abdominal pain, bloating, diarrhea, and constipation. In a study conducted by Calmino involving 1,003 users, 94% said Proibs was helpful, 91% reported an improvement in daily life, and 98% said they would recommend the product.The company said it is targeting a portion of the U.S. digestive and gut-health supplement market, which it estimates at $4.16 billion.The deal expands Immuron’s commercial portfolio beyond Travelan, an over-the-counter tablet to prevent diarrhea.<h2 class="st-heading-2">IMM-529 Is Immuron’s Next Big Bet</h2>Immuron is also advancing IMM-529, its experimental oral treatment for recurrent Clostridioides difficile infection, which can cause severe diarrhea. Last November, the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug application, allowing IMM-529 to move toward a Phase 2 trial.Healthcare consultancy firm Lumanity estimates IMM-529’s peak U.S. sales of $400 million.<h2 class="st-heading-2">Retail Flags ‘Insane’ Volumes</h2>Retail sentiment surrounding IMRN on Stocktwits flipped to ‘extremely bullish’ from ‘neutral,’ amid ‘extremely high’ message volumes.One user said the stock could climb to $5, highlighting the “insane volume.”<stembedurl>https://stocktwits.com/luckylunatic/message/663637534</stembedurl>More than 80 million shares changed hands, far exceeding the daily average of around 16,000, according to Stocktwits data.Another user highlighted $1.95 as key resistance.<stembedurl>https://stocktwits.com/SmartMoneyTradez/message/663632669</stembedurl>The stock has gained around 135% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/planet-labs-is-on-a-roll-in-defense-and-intelligence-says-craig-hallum-why-did-the-firm-shave-its-target-by-over-28/cZsD38LRJwC">Planet Labs Is ‘On A Roll’ In Defense And Intelligence, Says Craig-Hallum — Why Did The Firm Shave Its Target By Over 28%?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market data with uptrend vector | Illustration Source: Getty Images

IMMURON Ltd/S ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.88
Prev Close	$0.9224
Open	$0.90
Dividend Yield	0.00%
50-Day Moving Average	$1.15
Beta	0.78
Avg. Volume	6.24M
PE Ratio	-2.61

52-Week High	$2.00
52-Week Low	$0.6765
Market Capitalization	$7.1M
EPS (Annual)	-$0.3358
Price to Book	0.92
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

IMRN Fundamentals